网站首页
概要
The EasySep™ HLA B Cell Enrichment Kit is designed to isolate B cells from fresh or previously frozen peripheral blood mononuclear cells by negative selection. Unwanted cells are targeted for removal with Tetrameric Antibody Complexes recognizing non-B cells and dextran-coated magnetic particles. The labeled cells are separated using an EasySep™ magnet and without the use of columns. Desired cells are poured off into a new tube and are ready for serology or flow cytometry crossmatch assays.
技术资料
| Document Type | 产品名称 | Catalog # | Lot # | 语言 |
|---|---|---|---|---|
| Product Information Sheet | EasySep™ HLA B Cell Enrichment Kit | 19054HLA | All | English |
| Product Information Sheet | RoboSep™ HLA B Cell Enrichment Kit with Filter Tips | 19054HLARF | All | English |
| Safety Data Sheet 1 | EasySep™ HLA B Cell Enrichment Kit | 19054HLA | All | English |
| Safety Data Sheet 2 | EasySep™ HLA B Cell Enrichment Kit | 19054HLA | All | English |
| Safety Data Sheet 1 | RoboSep™ HLA B Cell Enrichment Kit with Filter Tips | 19054HLARF | All | English |
| Safety Data Sheet 2 | RoboSep™ HLA B Cell Enrichment Kit with Filter Tips | 19054HLARF | All | English |
数据及文献
Data
Figure 1. FACS Histogram Results with EasySep™ HLA B Cell Enrichment Kit
Starting with frozen mononuclear cells, the CD19+ cell content of the enriched fraction typically ranges from 95 - 99%.
Publications (1)
Transplantation proceedings 2013
Modified flow cytometry crossmatch detecting alloantibody-related cytotoxicity as a way to distinguish lytic antibodies from harmless in allosensitised kidney recipients.
Abstract
Abstract
The serological complement-dependent cytotoxicity crossmatch (CDC-XM) permits routine identification of anti-donor alloantibodies in the sera of allotransplant recipients. However, in a small group of recipients, antibodies below the threshold of detection may still be responsible for hyperacute rejection. For the same reason, approximately 20% of recipients develop acute rejection episodes. The flow cytometry crossmatch (FCXM) was designed to address these problems, but because of the presence of clinically insignificant antibodies (linked, non-lytic), the FCXM appears to be too sensitive yielding false-positive results. We compared FCXM with its modified version assessing cell viability (cytolytic flow cytometry crossmatch; cFCXM) using sera from previously sensitised kidney recipients. The presence of alloantibodies was detected using the Luminex platform. The cFCXM proved to be of greater sensitivity than CDC-XM, which was additionally confirmed with bead-based Luminex techniques. The cFCXM was also superior to FCXM because it distinguished lytic from non-lytic antibodies. The cFCXM was superior to assess donor specificity, sensitivity, and detection of clinically relevant lytic antibodies.
